Med. praxi. 2024;21(1):61-66 | DOI: 10.36290/med.2024.004

What to consider when choosing the most appropriate anticoagulant for a particular patient?

prof. MUDr. Jan Bultas, CSc.
Ústav farmakologie, 3. LF UK, Praha

There are currently several oral anticoagulants available for the treatment and prevention of thrombotic and thromboembolic conditions: antivitamin K - warfarin, and four direct anticoagulants - apixaban, edoxaban, rivaroxaban, and dabigatran. For several years, the prescription of direct anticoagulants has not been relaxed for general practitioners for economic reasons. Now that generic products are coming in and the price is inevitably decreasing, it is highly likely to extend the prescription, respectively to leave only the indication limitation. This article aims to summarize the basic properties, advantages, and weaknesses and the selection of the optimal anticoagulant for a particular patient.

Keywords: choice of anticoagulant, apixaban, edoxaban, rivaroxaban, dabigatran, warfarin.

Received: September 27, 2023; Revised: January 30, 2024; Accepted: January 30, 2024; Published: March 6, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bultas J. What to consider when choosing the most appropriate anticoagulant for a particular patient? Med. praxi. 2024;21(1):61-66. doi: 10.36290/med.2024.004.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bracey A, Shatila W, Wilson J. Bleeding in patients receiving non­‑vitamin K oral anticoagulants: clinical trial evidence. Ther Adv Cardiovasc, DiS. 2018 Dec;12(12):361-380. doi: 10.1177/1753944718801554. Epub 2018 Sep 30. PMID: 30270775; PMCID: PMC6266250. Go to original source... Go to PubMed...
    2. Steffel J, Verhamme P, Potpara TS, et al; ESC Scientific Document Group. The 2018 European Heart Rhythm Association Practical Guide on the use of non­‑vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018 Apr 21;39(16):1330-1393. doi: 10.1093/eurheartj/ehy136. PMID: 29562325. Go to original source... Go to PubMed...
    3. Joosten LPT, van Doorn S, van de Ven PM, et al. Safety of Switching From a Vitamin K Antagonist to a Non­‑Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL­‑AF Randomized Controlled Trial. Circulation. 2024 Jan 23;149(4):279-289. doi: 10.1161/CIRCULATIONAHA.123.066485. Epub 2023 Aug 27. PMID: 37634130. Go to original source... Go to PubMed...

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.